Compare APG & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APG | JAZZ |
|---|---|---|
| Founded | 1926 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 16.1B |
| IPO Year | 2019 | 2007 |
| Metric | APG | JAZZ |
|---|---|---|
| Price | $40.02 | $246.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $46.33 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 2.3M | 924.3K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.86 | N/A |
| EPS | 0.32 | ★ 7.17 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $8.86 | $6.22 |
| Revenue Next Year | $6.04 | $7.68 |
| P/E Ratio | $124.47 | ★ $34.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.40 | $123.89 |
| 52 Week High | $49.99 | $266.38 |
| Indicator | APG | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 48.05 |
| Support Level | $38.18 | $237.05 |
| Resistance Level | $40.10 | $265.71 |
| Average True Range (ATR) | 1.15 | 7.82 |
| MACD | -0.32 | -1.03 |
| Stochastic Oscillator | 20.25 | 25.75 |
APi Group Corp operates in two segments: Safety Services segment includes providing safety services in North America, Asia Pacific, and Europe, focusing on end-to-end integrated occupancy systems (fire protection solutions, Heating, Ventilation, and Air Conditioning and entry systems), including design, installation, inspection, and service of these integrated systems. These services are provided in commercial, education, healthcare, high tech, industrial, and special-hazard settings. Specialty Services segment includes providing a variety of infrastructure services and specialized industrial plant services, which include maintenance and repair of critical infrastructure such as underground electric, gas, water, sewer, and telecommunications infrastructure.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.